Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.

ABSTRACT:

Purpose

The mesothelin-targeting antibody-drug conjugate anetumab ravtansine was evaluated in combination with the programmed cell death-1 (PD-1) inhibitor pembrolizumab based on the common expression of mesothelin and reports of activity in mesothelioma.

Patients and methods

A phase 1 safety run-in of the combination of anetumab ravtansine (6.5 mg/kg iv q3weeks) and pembrolizumab (200 mg, IV q3weeks) was conducted, followed by a phase 2 randomization to the combination or pembrolizumab alone at medical centers across the United States and Canada in the National Cancer Institute's Experimental Therapeutics Clinical Trials Network. Patients with pleural mesothelioma that expressed mesothelin and had previously received platinum-based therapy were eligible.

Results

In p

SUBMITTER: Mansfield AS 

PROVIDER: S-EPMC11416719 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature